First AI-designed drug reaches Phase III

Insilico Medicine's Rentosertib for idiopathic pulmonary fibrosis (IPF) has advanced to Phase III clinical trials, a historic milestone as the first AI-discovered drug to reach this stage. No AI-designed drug has yet received FDA approval, but this marks a significant step forward.